Last, in a dataset with concomitant transcriptome and CD5 immunochemistry staining GSE66770, the majority (17/22; 77.2%) of the top 25% samples were CD5+ DLBCL (2.1-fold enrichment) while this proportion was significantly lower (16/68; 23.5%) in the rest of the cohort (p = 4.73e−3). This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.